Characteristics of clinically classified IM responders and IM nonresponders
| Characteristic . | IM responders . | IM nonresponders . | P* . |
|---|---|---|---|
| Quantitative features | |||
| WBC at diagnosis | Range: [25.5, 450]; mean, 149; CI: [62.9, 235] | Range: [32.2, 536] mean, 204; CI: [101, 252] | .42 |
| Age, y | Range: [23,76]; mean, 52.64; CI: [49.47, 55.80] | Range: [29,77]; mean, 55.71; CI: [53.86, 57.57] | .60 |
| Mutant BCR-ABL transcripts, percentage | Range: [0, 20]; mean, 10.1; CI: [8.3, 12.2] | Range: [9, 40]; mean, 24.5; CI: [21.5, 26.5] | < .003† |
| NA | 1 (9.1%) | 4 (28.6%) | |
| No. of colonies as percentage of untreated cells CFC IM 1μM | Range: [14.2, 53]; mean, 35.6; CI: [32.7, 38.4] | Range: [40.6, 92] mean, 60.1; CI: [57.6, 62.6] | < .001 |
| CFC IM 5μM | Range: [7.7, 42.6]; mean, 22.7; CI: [20.5, 24.9] | Range: [34, 64]; mean, 48.66; CI: [47.4, 49.9] | < .001 |
| CFC IM 10μM | Range: [6.6, 42]; mean, 22.3; CI: [20, 24.6] | Range: [20.8, 61.3]; mean, 44.0; CI: [41.8, 46.1] | < .001 |
| Time from diagnosis to IM treatment, d | Range: [7, 335]; mean, 60.36; CI: [-122, 242] | Range: [7, 377]; mean, 107; CI: [-133, 347] | .29 |
| Qualitative features | |||
| Sokal risk score | .928‡ | ||
| Low | 1 (14.3%); CI: NA§ | 2 (9.1%); CI: [0.14, 1.22] | |
| Intermediate | 7 (42.9%); CI: [0.84, 0.94] | 6 (63.6%); CI: [0.89, 0.96] | |
| High | 3 (35.7%); CI: [0.58, 2.9] | 5 (27.3%); CI: [1.56, 2.55] | |
| NA | 0 | 1 (7.14%) | |
| Sex | > .311‖ | ||
| Male | 6 (54.6%) | 8 (57.1%) | |
| Female | 5 (45. 5%) | 6 (42.9%) | |
| Prior interferon | > .158‖ | ||
| Yes | 0 | 3 (21.4%) | |
| No | 11 (100%) | 11 (78.6%) | |
| Prior hydroxyurea | .072‖ | ||
| Yes | 7 (63.6%) | 14 (100%) | |
| No | 4 (36.4%) | 0 | |
| Daily IM dose | .161‡ | ||
| 400 mg | 9 (81.8%) | 8 (57.4%) | |
| 400-600 mg | 2 (18.2%) | 4 (28.6%) | |
| 400-800 mg | 0 | 2 (14.3%) | |
| Primary/secondary resistance | < .001 | ||
| NA¶ | 11 (100%) | 0 | |
| Primary resistance | 0 | 9 (64.3%) | |
| Secondary resistance | 0 | 5 (35.7%) |
| Characteristic . | IM responders . | IM nonresponders . | P* . |
|---|---|---|---|
| Quantitative features | |||
| WBC at diagnosis | Range: [25.5, 450]; mean, 149; CI: [62.9, 235] | Range: [32.2, 536] mean, 204; CI: [101, 252] | .42 |
| Age, y | Range: [23,76]; mean, 52.64; CI: [49.47, 55.80] | Range: [29,77]; mean, 55.71; CI: [53.86, 57.57] | .60 |
| Mutant BCR-ABL transcripts, percentage | Range: [0, 20]; mean, 10.1; CI: [8.3, 12.2] | Range: [9, 40]; mean, 24.5; CI: [21.5, 26.5] | < .003† |
| NA | 1 (9.1%) | 4 (28.6%) | |
| No. of colonies as percentage of untreated cells CFC IM 1μM | Range: [14.2, 53]; mean, 35.6; CI: [32.7, 38.4] | Range: [40.6, 92] mean, 60.1; CI: [57.6, 62.6] | < .001 |
| CFC IM 5μM | Range: [7.7, 42.6]; mean, 22.7; CI: [20.5, 24.9] | Range: [34, 64]; mean, 48.66; CI: [47.4, 49.9] | < .001 |
| CFC IM 10μM | Range: [6.6, 42]; mean, 22.3; CI: [20, 24.6] | Range: [20.8, 61.3]; mean, 44.0; CI: [41.8, 46.1] | < .001 |
| Time from diagnosis to IM treatment, d | Range: [7, 335]; mean, 60.36; CI: [-122, 242] | Range: [7, 377]; mean, 107; CI: [-133, 347] | .29 |
| Qualitative features | |||
| Sokal risk score | .928‡ | ||
| Low | 1 (14.3%); CI: NA§ | 2 (9.1%); CI: [0.14, 1.22] | |
| Intermediate | 7 (42.9%); CI: [0.84, 0.94] | 6 (63.6%); CI: [0.89, 0.96] | |
| High | 3 (35.7%); CI: [0.58, 2.9] | 5 (27.3%); CI: [1.56, 2.55] | |
| NA | 0 | 1 (7.14%) | |
| Sex | > .311‖ | ||
| Male | 6 (54.6%) | 8 (57.1%) | |
| Female | 5 (45. 5%) | 6 (42.9%) | |
| Prior interferon | > .158‖ | ||
| Yes | 0 | 3 (21.4%) | |
| No | 11 (100%) | 11 (78.6%) | |
| Prior hydroxyurea | .072‖ | ||
| Yes | 7 (63.6%) | 14 (100%) | |
| No | 4 (36.4%) | 0 | |
| Daily IM dose | .161‡ | ||
| 400 mg | 9 (81.8%) | 8 (57.4%) | |
| 400-600 mg | 2 (18.2%) | 4 (28.6%) | |
| 400-800 mg | 0 | 2 (14.3%) | |
| Primary/secondary resistance | < .001 | ||
| NA¶ | 11 (100%) | 0 | |
| Primary resistance | 0 | 9 (64.3%) | |
| Secondary resistance | 0 | 5 (35.7%) |
NA indicates not available.
P values were calculated using the Welch 2-sample t test at the 5% significant level under the null hypothesis H0: mean (IM responders) = mean (IM nonresponders).
P value of mutant BCR-ABL transcript frequency was calculated after all the missing values were taken out of the sample.
Kruskal-Wallis test was used to calculate P values of ordered categorical variable for Sokal risk score and daily IM dose.
CI for low IM responders in the low Sokal risk group is not available because there is only one patient in this category.
Fisher exact test was used to calculate P values of nonordered categorical variable for sex, prior interferon, and prior hydroxyurea.
Primary/secondary resistance is not available for all IM responders.